BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer
9 of 11 women remain alive from 2021/2022 dosing, highlighting strong survival benefits.Remains well tolerated with no dose limiting toxicities.Primary...
Clinical Trial
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2...
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused...
ReWalk Robotics Reports Fourth Quarter and Full Year 2022 Financial Results
Strong Conclusion to 2022 – Q4’22 Revenue Highest Since Start of COVID-19 Pandemic Record Quarterly MyoCycle Sales Supplement Improved Exoskeleton...
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022 Total Revenue of $164.4 Million,...
SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced...
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application
PALO ALTO, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for...
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
CELEBRATION, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.),...
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30...
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer – – Presented Phase...
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community Branding reflects Company’s commitment to making...
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
Final draft guidance based on cost effectiveness evaluation of sotrovimabSAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc....
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
WARREN, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company...
Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a preclinical-stage biotechnology company committed to...
Oncocyte Completes Razor Genomics Transaction
Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product...
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology
Monday, February 27th at 10am ETMADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code:...
Amarin to Present at Cowen’s 43rd Annual Health Care Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail,...
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...